You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BERTEC CORP Topic: NIA
Falls are a significant source of early morbidity and mortality in the aging population, yet the neurological,sensory, and motor changes that lead to increased fall risk often escape early identification and intervention. Vital signs are commonly used in clinical settings to assess the cardiovascular system (blood pressure, heart rate), immune system (body temperature), and the respiratory system ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesiaSBC: Sentiomed, Inc. Topic: 300
PROJECT SUMMARY ABSTRACT The opioid fentanyl is administered in millions of procedural sedations every yearIt is very potenthas large interpatient pharmacokinetic variabilityand routinely causes significant respiratory depression if bolused or not titrated judiciouslyDosing and timingcritical for safety and efficacyare presently only possible based on educated guesses and vital signsSedation assoc ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturingSBC: Bondwell Technologies Inc. Topic: 400
Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's DiseaseSBC: Amprion, Inc. Topic: NIA
This proposal is for a phase I/II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluids, which could be used for the biochemical diagnosis of Alzheimer’s disease (AD) and related tauopathies. AD is the most common dementia in the elderly population and one of the leading causes of death in the developed wor ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Biospyder Technologies, Inc. Topic: 172
SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Oncosynergy, Inc. Topic: 102
PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Vova Ida, LLC Topic: 999
SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOMIMETIX JV LLC Topic: 102
Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Microsurgical Innovations Inc Topic: 999
Project Summary Nerve injury can occur due to traumachronic compression or disease processes such as diabetes or tumors and have a tremendous socioeconomic impact from loss of work and healthcare costsThere is still a clinical need to improve recovery from nerve injuriesand a new nerve conduit drug delivery device that addresses this clinical need is the focus of the present proposalOur group has ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health